International Stem Cell (ISCO) Operating Leases (2019 - 2025)
International Stem Cell (ISCO) posted quarterly Operating Leases of $103000.0 for Q3 2025, down 49.26% year-over-year from $203000.0 in Q3 2024, and down 49.51% quarter-over-quarter from $204000.0 in Q2 2025.
International Stem Cell (ISCO) Operating Leases (2019 - 2025) Analysis & Trends
International Stem Cell (ISCO) has reported Operating Leases for 7 consecutive years, with $103000.0 the latest figure, recorded in Q3 2025.
- In Q3 2025, Operating Leases fell 49.26% year-over-year to $103000.0; the TTM figure through Sep 2025 stood at $103000.0 (down 49.26% YoY), while the FY2024 annual figure was $115000.0, down 74.16% from the prior year.
- Operating Leases slipped to $103000.0 in Q3 2025 per ISCO's latest filing, from $204000.0 in the prior quarter.
- Across five years, Operating Leases topped out at $950000.0 in Q4 2021 and bottomed at $103000.0 in Q3 2025.
- Historically, Operating Leases has averaged $532315.8 across 5 years, with a median of $588000.0 in 2023.
- Annual changes were most pronounced in 2022 — Operating Leases gained 21.09% — and 2024, when it tumbled 74.16%.
- International Stem Cell's Operating Leases stood at $950000.0 in 2021, then slipped by 24.21% to $720000.0 in 2022, then plunged by 38.19% to $445000.0 in 2023, then sank by 74.16% to $115000.0 in 2024, then slipped by 10.43% to $103000.0 in 2025.
- Business Quant data shows ISCO's Operating Leases at $103000.0 in Q3 2025, $204000.0 in Q2 2025, and $302000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.69 Bn | 130.84 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.29 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.79 Bn | 59.60 Bn | 1.37 Bn |
| 4 | Moderna | 59.44 Bn | 54.31 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.92 Bn | 27.61 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.10 Bn | 9.71 Bn | 668.28 Mn |
| 8 | Insmed | 27.33 Bn | 26.17 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.00 Bn | 26.17 Bn | - |
| 10 | International Stem Cell | 4.32 Mn | 3.23 Mn | 1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 103,000.00 |
| Jun 30, 2025 | 204,000.00 |
| Mar 31, 2025 | 302,000.00 |
| Dec 31, 2024 | 115,000.00 |
| Sep 30, 2024 | 203,000.00 |
| Jun 30, 2024 | 286,000.00 |
| Mar 31, 2024 | 367,000.00 |
| Dec 31, 2023 | 445,000.00 |
| Sep 30, 2023 | 518,000.00 |
| Jun 30, 2023 | 588,000.00 |
| Mar 31, 2023 | 656,000.00 |
| Dec 31, 2022 | 720,000.00 |
| Sep 30, 2022 | 781,000.00 |
| Jun 30, 2022 | 840,000.00 |
| Mar 31, 2022 | 896,000.00 |
| Dec 31, 2021 | 950,000.00 |
| Sep 30, 2021 | 645,000.00 |
| Jun 30, 2021 | 714,000.00 |
| Mar 31, 2021 | 781,000.00 |
| Dec 31, 2020 | 845,000.00 |